Results 11 to 20 of about 3,566 (133)
N-terminal pro-brain natriuretic peptide and cardiorenal outcome in patients with anaemia in chronic kidney disease. [PDF]
ESC Heart FailAbstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Nishi H +4 more
europepmc +2 more sources
A New Rapid and Specific Iodination Reagent for Phenolic Compounds
Organics, 2023 A new rapid iodination reagent, N1,N3,N5-tris[(2,4,6-trimethylpyridine)iodo(I)]-2,4,6-triphenyl-s-triazine trihexafluorophosphate, was synthesized in a modification of the established synthesis of 2,4,6-triiodo-3,5-dimethylphenol in the presence of bis(2,
Till Hauenschild, Dariush Hinderberger
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2015 Sympathetic activation during acute myocardial infarction is an important arrhythmogenic mechanism, but the role of central autonomic inputs and their modulating factors remain unclear. Using the in vivo rat-model, we examined the effects of clonidine, a
Theofilos M Kolettis +10 more
doaj +1 more source
Dexmedetomidine in Current Anaesthesia Practice- A Review [PDF]
Journal of Clinical and Diagnostic Research, 2014 Dexmedetomidine is an alpha 2 adrenergic receptor agonist, even ten times more selective than clonidine. It is a very versatile drug in anaesthesia practice, finding place in increasing number of clinical scenarios and is no more limited to intensive ...
Shagufta Naaz, Erum Ozair
doaj +1 more source
Bucindolol: A Pharmacogenomic Perspective on its Use in Chronic Heart Failure
Clinical Medicine Insights: Cardiology, 2011 Bucindolol is a non-selective β-adrenergic receptor blocker with α-1 blocker properties and mild intrinsic sympatholytic activity. The Beta-Blocker Evaluation of Survival Trial (BEST), which is the largest clinical trial of bucindolol in patients with ...
Neil A. Smart +4 more
doaj +1 more source
Hypertension management: Old drug revisited - Cilnidipine
Journal of Clinical and Preventive Cardiology, 2017 Cilnidipine is a promising fourth-generation calcium channel blocker which along with inhibition of the L-type Ca 2+ channels in vascular smooth muscle cells, also inhibits the N-type Ca 2+ channels in sympathetic neurons.
Soumitra Kumar
doaj +1 more source
Sympathetic activity and arterial hypertension: potential for correction
Российский кардиологический журнал, 2013 The paper is focussed on the role of increased sympathetic activation in the pathogenesis of arterial hypertension (AH), its exacerbations (hypertensive crises), and complications.
O. Yu. Shayduk, E. O. Taratukhin
doaj +1 more source
Dopaminergic agonist bromocriptin in treatment of diabetes mellitus type 2
Ожирение и метаболизм, 2011 Bromocriptine is a sympatholytic agonist of dopamine receptors, which is now proposed for treatment of type 2 diabetes mellitus. In animal studies bromocriptine elevates the decreased levels of dopamine in hypothalamus and blocks excessive sympathetic ...
O. A. Gerasimenko +2 more
doaj +1 more source
Adjuvant dexmedetomidine in treatment of alcohol withdrawal delirium: Case series
Medical Journal of Dr. D.Y. Patil Vidyapeeth, 2023 Alcohol withdrawal delirium is a medical emergency with mortality rates of 20–50% without treatment. Benzodiazepines (BZDs) (gamma-aminobutyric acid receptor agonists) are the mainstay of treatment.
Amit Chail +3 more
doaj +1 more source
Menopause and autonomic control of heart
Medical Journal of Dr. D.Y. Patil University, 2012 Menopause is associated with decreased heart rate variability, which is due to reduced parasympathetic or increased sympathetic outflow to the heart. Acute myocardial infarction may be accompanied by decreased heart rate variability.
Arunima Chaudhuri, Nirmala G Borade
doaj +1 more source